BioNTech SE stock gains as Berenberg lifts price target after recent pullback

Published on 09/21/2026 at 12:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BioNTech SE stock is supported by a fresh Berenberg Buy rating and a higher USD 140 price target as of September 21, 2026. Recent trading shows the shares below fair value estimates after a pullback, keeping the pipeline in focus for investors.

BioNTech SE, US09075V1026, Illustration mit AI erstellt.

BioNTech SE stock (ISIN US09075V1026) is drawing renewed interest from investors after private bank Berenberg raised its price target to USD 140 and reiterated a Buy rating on September 21, 2026, while the shares recently closed at USD 96.06 on Nasdaq, pointing to upside versus valuation models.

Berenberg raises target on oncology and vaccine pipeline

According to Finanznachrichten on September 21, 2026, Berenberg lifted its price target for BioNTech from USD 132 to USD 140 and maintained a Buy recommendation, highlighting the company’s oncology pipeline as a key driver alongside its established Covid-19 franchise.

In contrast, BMO Capital Markets turned more cautious earlier in the month, cutting its rating from Outperform to Market Perform and reducing its target from USD 128 to USD 105 on September 8, 2026, citing weaker global Covid-19 vaccine demand and inventory reductions in Germany, as reported by Stock-World.

Valuation context: share price lags fair value estimates

As of a recent analysis dated September 20, 2026, BioNTech shares closed at USD 96.06 on Nasdaq, while a discounted cash flow and scenario-based valuation pointed to a fair value of around USD 118.06, implying that the stock might be approximately 19 percent undervalued relative to those assumptions, according to Simply Wall St.

The same analysis notes that BioNTech’s 30 day share price return was down 17.6 percent, while the 90 day share price return was up 6.5 percent and the one year total shareholder return was roughly flat, underscoring how short term volatility has contrasted with a more stable longer term performance profile, as outlined by Simply Wall St.

Fundamental backdrop and pipeline expectations

While the week-filtered search results focus on ratings and valuation context rather than publishing a new quarterly release, the current analyst discourse reflects a balance between near term Covid-19 vaccine revenue pressure and anticipation for oncology and next generation immunotherapy programs. Berenberg’s higher target of USD 140 versus BMO’s reduced USD 105 level illustrates the spread between more optimistic and more cautious scenarios for BioNTech’s earnings and cash flow trajectory, as seen in the coverage by Finanznachrichten and Stock-World.

Investors following BioNTech SE stock therefore weigh the current price of USD 96.06 and its distance to valuation markers like the USD 118.06 fair value estimate and Berenberg’s USD 140 target, while also noting that BMO’s USD 105 target now sits below Berenberg’s view but still above the recent close, defining a range of roughly 9 to 45 percent potential upside depending on which scenario one considers, based on the figures cited by Simply Wall St, Finanznachrichten and Stock-World.

BioNTech SE stock price snapshot

For orientation, BioNTech SE’s American Depositary Receipts trade on Nasdaq under the ticker BNTX, with the recent closing price of USD 96.06 on September 20, 2026 serving as a reference point for current valuations in the stock.